Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Predictor of Liver Biochemistry Improvement in Patients with Cytomegalovirus Cholestasis after Ganciclovir Treatment

  • Puspita, Gina (Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital) ;
  • Widowati, Titis (Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital) ;
  • Triono, Agung (Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital)
  • Received : 2020.06.17
  • Accepted : 2021.10.11
  • Published : 2022.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Cholestasis resulting from cytomegalovirus (CMV)-induced hepatitis manifests in 40% of patients with a CMV infection. Ganciclovir treatment in children with CMV infections has proven to be highly effective. Until now, there are very few studies have identified predictive factors for liver biochemistry improvement after ganciclovir therapy. This study aimed to identify the predictors of liver biochemistry improvement in patients with CMV cholestasis after ganciclovir treatment. Methods: A retrospective cohort study was conducted using medical records from Dr. Sardjito General Hospital Yogyakarta, Indonesia from 2013 to 2018. CMV cholestasis was confirmed based on serum CMV IgG and IgM positivity and/or blood and urine CMV antigenemia positivity. Incomplete medical records and other etiologies for cholestasis, such as biliary atresia, choledochal cyst, metabolic diseases, and Alagille syndrome, were excluded. Patient age at cholestasis diagnosis and ganciclovir treatment, duration of CMV cholestasis, history of prematurity, central nervous system involvement, and nutritional status were analyzed and presented as an odds ratio (OR) with a 95% confidence interval (95% CI). Results: CMV cholestasis with ganciclovir therapy was found in 41 of 54 patients. Multivariate analysis showed that a shorter duration of CMV cholestasis (OR: 4.6, 95% CI: 1.00-21.07, p=0.04) was statistically significant for liver biochemistry improvement after 1 month of ganciclovir treatment. The remaining factors that were analyzed were not significant predictors of liver biochemistry improvement in patients with CMV cholestasis after ganciclovir treatment. Conclusion: A shorter duration of CMV cholestasis is the predictor of liver biochemistry improvement after 1 month gancyclovir treatment.

Keywords

References

  1. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick, & Adelberg's medical microbiology. 26th ed. New York: McGraw-Hill, 2013:480-3.
  2. Hasosah MY, Kutbi SY, Al-Amri AW, Alsahafi AF, Sukkar GA, Alghamdi KJ, et al. Perinatal cytomegalovirus hepatitis in Saudi infants: a case series. Saudi J Gastroenterol 2012;18:208-13. https://doi.org/10.4103/1319-3767.96461
  3. Liberek A, Rytlewska M, Szlagatys-Sidorkiewicz A, Bako W, Luczak G, Sikorska-Wisniewska G, et al. Cytomegalovirus disease in neonates and infants--clinical presentation, diagnostic and therapeutic problems--own experience. Med Sci Monit 2002;8:CR815-20.
  4. Tezer H, Secmeer G, Kara A, Ceyhan M, Cengiz AB, Devrim I, et al. Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children. Turk J Pediatr 2008;50:228-34.
  5. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007;17:355-63. https://doi.org/10.1002/rmv.544
  6. Leonardsson H, Hreinsson JP, Love A, Bjornsson ES. Hepatitis due to Epstein-Barr virus and cytomegalovirus: clinical features and outcomes. Scand J Gastroenterol 2017;52:893-7. https://doi.org/10.1080/00365521.2017.1319972
  7. Whitley RJ, Cloud G, Gruber W, Storch GA, Demmler GJ, Jacobs RF, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997;175:1080-6. https://doi.org/10.1086/516445
  8. Mattar RH, Azevedo RA, Speridiao PG, Fagundes Neto U, Morais MB. [Nutritional status and intestinal iron absorption in children with chronic hepatic disease with and without cholestasis]. J Pediatr (Rio J) 2005;81:317-24. Portuguese. https://doi.org/10.2223/1369
  9. Rosenthal P. Neonatal hepatitis and congenital infection. In: Suchy FJ, Sokol RJ, Balistreri WF, eds. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007:232-46.
  10. Min CY, Song JY, Jeong SJ. Characteristics and prognosis of hepatic cytomegalovirus infection in children: 10 years of experience at a university hospital in Korea. Korean J Pediatr 2017;60:261-5. https://doi.org/10.3345/kjp.2017.60.8.261
  11. Tezer H, Kanik Yuksek S, Gulhan B, Ozkaya Parlakay AN, Tuna Kirsaclioglu C. Cytomegalovirus hepatitis in 49 pediatric patients with normal immunity. Turk J Med Sci 2016;46:1629-33. https://doi.org/10.3906/sag-1507-161
  12. Schleiss MR. Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis. Infect Disord Drug Targets 2011;11:449-65. https://doi.org/10.2174/187152611797636721
  13. Ross SA, Boppana SB. Congenital cytomegalovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis 2005;16:44-9. https://doi.org/10.1053/j.spid.2004.09.011
  14. Pawlowska J, Swiatkowska E, Gliwicz D, Jankowska I, Kluge P, Cukrowska B, et al. The role of cytomegalovirus infection in pathogenesis of neonatal cholestasis. Exp Clin Hepatol 2010;6:25-9.
  15. Kunno A, Abe M, Yamada M, Murakami K. Clinical and histological features of cytomegalovirus hepatitis in previously healthy adults. Liver 1997;17:129-32. https://doi.org/10.1111/j.1600-0676.1997.tb00794.x
  16. Greanya ED, Partovi N, Yoshida EM, Shapiro RJ, Levy RD, Sherlock CH, et al. The role of the cytomegalovirus antigenemia assay in the detection and prevention of cytomegalovirus syndrome and disease in solid organ transplant recipients: a review of the British Columbia experience. Can J Infect Dis Med Microbiol 2005;16:335-41. https://doi.org/10.1155/2005/679386
  17. Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets 2011;11:466-74. https://doi.org/10.2174/187152611797636703